Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vorinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 17/20 | 1.00 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 16/20 | 1.00 |
| ▸ | HDAC3 known ✓ | O15379 | 14/20 | 1.00 |
| ▸ | HDAC2 known ✓ | Q92769 | 14/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 12/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 12/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | NCOR1 | O75376 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | LTA4H | P09960 | 1/20 | 1.00 |
| ▸ | NR0B1 | P51843 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055010 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL19754407 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL8261596 | 1.00 | HDAC1 (1.00) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL23055007 | 0.98 | HDAC1 (0.96) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| Vorinostat SCHEMBL28095919 | 0.95 | HDAC1 (0.90) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL12659217 | 0.94 | HDAC1 (0.89) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL30535798 | 0.93 | HDAC6 (0.87) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL137348 | 0.92 | HDAC4 (0.85) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL6669511 | 0.92 | HDAC4 (0.85) | HDAC1HDAC6HDAC3HDAC2HDAC11 | |
| SCHEMBL1065393 | 0.92 | HDAC4 (0.85) | HDAC1HDAC6HDAC3HDAC2HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 55731 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116209439-B | Cereblon protein modulators | Saint Jude Children's Research Hospital Ltd. (US) | 2026-05-26 | — | — | CN | claimed |
| US-12637498-B2 | PDLIM2 as a biomarker for cancer and as an anti-cancer treatment target | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2026-05-26 | — | — | US | claimed |
| CN-122075711-A | Application of histone deacetylase inhibitor HDACi in preparation of medicines for preventing and/or treating ammonia-induced encephalopathy | — | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122070932-A | Application of combination of decitabine and anti-HER 2 antibody in preparation of medicines for treating tumors | 上海交通大学 | 2026-05-22 | — | — | CN | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| WO-2026107052-A1 | COMBINATION TREATMENTS USING EPIGENETIC INHIBITION AND SYNGRI-MEDIATED FRATAXIN EXPRESSION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137685-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| US-20260137686-A1 | SOLID PHARMACEUTICAL FORMULATION OF PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS SHANGHAI INC (CN) | 2026-05-21 | — | — | US | claimed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | claimed |
| WO-2002085400-A1 | COMPOSITIONS AND METHODS FOR REESTABLISHING GENE TRANSCRIPTION THROUGH INHIBITION OF DNA METHYLATION AND HISTONE DEACETYLASE | SUPERGEN, INC. (US) | 2002-10-31 | — | — | WO | claimed |
| EP-1243290-A2 | Modulation of gene expression by combination therapy | Methylgene, Inc. (CA) | 2002-09-25 | — | — | EP | claimed |
| EP-1243289-A2 | Modulation of gene expression by combination therapy | Methylgene, Inc. (CA) | 2002-09-25 | — | — | EP | claimed |
| JP-2002528391-A | — | — | 2002-09-03 | — | — | JP | claimed |
| WO-2002060430-A1 | USE OF RETINOIDS PLUS HISTONE DEACETYLASE INHIBITORS TO INHIBIT THE GROWTH OF SOLID TUMORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| WO-2002055017-A2 | METHOD OF TREATING AUTOIMMUNE DISEASES | WAKE FOREST UNIVERSITY (US) | 2002-07-18 | — | — | WO | claimed |
| WO-2002022133-A1 | PROMOTION OF ADOPTOSIS IN CANCER CELLS BY CO-ADMINISTRATION OF CYCLIN DEPENDENT KINASE INHIBITORS AND CELLULAR DIFFERENTIATION AGENTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2002-03-21 | — | — | WO | claimed |
| EP-1123111-A1 | MODULATION OF DNA METHYLTRANSFERASE EXPRESSION BY COMBINATION THERAPY | Methylgene, Inc. (CA) | 2001-08-16 | — | — | EP | claimed |
| WO-2000023112-A9 | MODULATION OF GENE EXPRESSION BY COMBINATION THERAPY | METHYLGENE INC (CA) | 2000-08-31 | — | — | WO | claimed |
| WO-2000023112-A1 | MODULATION OF GENE EXPRESSION BY COMBINATION THERAPY | METHYLGENE, INC. (CA) | 2000-04-27 | — | — | WO | claimed |